Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease — Stella

Home/Peripheral Artery Disease (PAD)/

View on ClinicalTrials.gov

Recruiting

Back to Peripheral Artery Disease (PAD) trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Emory University Hospital, Atlanta, Georgia

Key details

Phase

Safety & dosing

Sponsor

Emory University

Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Enrollment target

~176 participants

Started

December 2017

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

Age range

21 Years – 85 Years

Last updated November 2024